• Теги
    • избранные теги
    • Компании2999
      • Показать ещё
      • Показать ещё
      Страны / Регионы393
      • Показать ещё
      Международные организации48
      • Показать ещё
      • Показать ещё
      • Показать ещё
      • Показать ещё
Gilead Sciences
28 июля, 17:57

United Therapeutics (UTHR) Incurs Loss in Q2, Sales Top

United Therapeutics Corporation (UTHR) incurred a loss in Q2. However, stronger sales across the PAH franchise pulled up the top line in the quarter.

28 июля, 15:54

4 Drug Stocks in Focus this World Hepatitis Day

Does the hepatitis C virus (HCV) market still hold potential for companies like Gilead (GILD)?

28 июля, 13:24

Сенаторы остановили рынок на полном ходу, - Павел Пахомов,руководитель учебного центра Санкт-Петербургской биржи

А все так хорошо начиналось. Отчетность, вышедшая до начала торгов - ну просто прелесть. Особенно хороши были данные от телекоммуникационного гиганта Verizon Communications (VZ, +7,68%). Да плюс, сохраняющийся позитив после выхода ночью отчетности Facebook (FB) и Gilead Sciences (GS). А еще - продолжающая расти нефть.

27 июля, 15:00

Gilead (GILD) Tops Q2 Earnings& Revenue Estimates, Stock Up

Gilead Sciences' (GILD) better-than-expected second-quarter results boosted investors sentiments.

Выбор редакции
27 июля, 00:22

Gilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats

Gilead Sciences (GILD) just released its second-quarter financial results, posting non-GAAP diluted earnings of $2.56 and revenues of $7.14 billion.

27 июля, 00:22

Gilead (GILD) Shares Pop on Q2 Earnings and Revenue Beats

Gilead Sciences (GILD) just released its second-quarter financial results, posting non-GAAP diluted earnings of $2.56 and revenues of $7.14 billion.

26 июля, 15:15

Biotech Stock Roundup: Amgen, Biogen Top Q2 Estimates, Update on Incyte RA Drug

Earnings season kicked off on a positive note for biotech stocks with big players like Amgen (AMGN) and Biogen reporting better than expected results.

25 июля, 18:18

Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK

We have three pharma giants that are set to report second-quarter results on Jul 26. Let's see how things are shaping up for this quarter.

25 июля, 17:42

Can Intercept (ICPT) Beat Estimates this Earnings Season?

Intercept Pharmaceuticals, Inc.'s (ICPT) lead drug Ocaliva's uptake has been encouraging and we expect the company to throw light on its label expansion when it reports second-quarter results.

25 июля, 16:42

Will Radius Health (RDUS) Disappoint this Earnings Season?

Radius Health Inc. (RDUS) is expected to throw light on the launch and uptake of its newly approved drug Tymlos when it reports second-quarter results.

25 июля, 15:30

Is a Surprise Coming for Gilead Sciences (GILD) This Earnings Season?

Gilead Sciences (GILD) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.

25 июля, 01:40

Biotech ETF Industry Outlook for Second Half 2017

There are several reasons to be positive on biotech stocks and ETFs for the rest of the year.

24 июля, 17:59

Is a Beat in Store for Agenus (AGEN) this Earnings Season?

Agenus Inc. (AGEN) will focus on the development of all its pipeline drugs as currently there are no marketed drug in its portfolio.

24 июля, 17:11

Surprise in Store for Healthcare in Q2: Buy Top-Ranked ETFs

Though the healthcare sector is expected to post an earnings decline and has a dismal Rank, some surprises may well be in the cards, suggesting upside for healthcare ETFs.

24 июля, 15:34

HIV fight advances with new drug cocktails, fresh vaccine hopes

THREE decades after approval of the first-ever AIDS treatment, HIV medicine is seeing a new wave of innovation with scientists reporting positive data on Monday for improved drug cocktails and a novel

Выбор редакции
24 июля, 14:16

Gilead Sciences says late-stage results for HIV drug combination are similar to standard of care

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

21 июля, 23:03

Biotech Bull is Back: 4 Keys to Play It

The bleeding edge of science offers riches, but there are 4 disciplines you must apply to win in this wild west.

21 июля, 21:46

Is a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?

Impressive performance of Vertex Pharmaceuticals' (VRTX) cystic fibrosis drugs Kalydeco and Orkambi may drive the stock to an earnings beat in Q2.

21 июля, 18:51

What to Expect from Keryx (KERX) this Earnings Season?

Keryx Biopharmaceuticals, Inc. (KERX) intends to focus on the growth of Auryxia in the U.S. dialysis market. The company is also making efforts for label expansion on Auryxia in the iron-deficiency anemia (IDA) indication.

21 июля, 18:23

What's in the Offing for Bristol-Myers (BMY) in Q2 Earnings?

Bristol-Myers Squibb Company (BMY) is scheduled to report first-quarter 2017 results on Jul 27, before the opening bell. Last quarter, the company beat earnings estimates by 16.7%.